Does the media prefer BNTX or PTGX?

In the previous week, BioNTech had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 10 mentions for BioNTech and 8 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.72 beat BioNTech's score of 0.59 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INSM or PTGX?

In the previous week, Insmed had 8 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 16 mentions for Insmed and 8 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 1.52 beat Protagonist Therapeutics' score of 0.72 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or PTGX?

In the previous week, Protagonist Therapeutics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.42 beat Protagonist Therapeutics' score of 0.72 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTGX or MRNA?

In the previous week, Moderna had 19 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 27 mentions for Moderna and 8 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.72 beat Moderna's score of 0.46 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral

Protagonist Therapeutics (PTGX) Competitors

$95.41 +2.18 (+2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$95.39 -0.02 (-0.02%)

As of 04:55 PM Eastern

Compare

PTGX vs. BNTX, INSM, ROIV, MRNA, and VTRS

Should you buy Protagonist Therapeutics stock or one of its competitors? MarketBeat compares Protagonist Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Protagonist Therapeutics include BioNTech (BNTX), Insmed (INSM), Roivant Sciences (ROIV), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Protagonist Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

BioNTech has a net margin of -44.39% compared to Protagonist Therapeutics' net margin of -154.88%. BioNTech's return on equity of -5.30% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

BioNTech currently has a consensus target price of $129.56, suggesting a potential upside of 46.48%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 20.76%. Given BioNTech's higher probable upside, equities research analysts plainly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

15.5% of BioNTech shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics has lower revenue, but higher earnings than BioNTech. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.89	-$1.29B	-$5.88	N/A
Protagonist Therapeutics	$46.02M	133.33	-$130.15M	-$1.81	N/A

In the previous week, BioNTech had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 10 mentions for BioNTech and 8 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.72 beat BioNTech's score of 0.59 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Summary

BioNTech beats Protagonist Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Insmed had 8 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 16 mentions for Insmed and 8 mentions for Protagonist Therapeutics. Insmed's average media sentiment score of 1.52 beat Protagonist Therapeutics' score of 0.72 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Insmed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Insmed has a net margin of -144.44% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Insmed currently has a consensus target price of $210.95, indicating a potential upside of 103.11%. Protagonist Therapeutics has a consensus target price of $115.21, indicating a potential upside of 20.76%. Given Insmed's stronger consensus rating and higher probable upside, research analysts clearly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Protagonist Therapeutics has lower revenue, but higher earnings than Insmed. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$819.56M	27.47	-$1.28B	-$5.75	N/A
Protagonist Therapeutics	$46.02M	133.33	-$130.15M	-$1.81	N/A

Summary

Insmed and Protagonist Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Protagonist Therapeutics has a net margin of -154.88% compared to Roivant Sciences' net margin of -3,629.19%. Protagonist Therapeutics' return on equity of -17.76% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Protagonist Therapeutics has higher revenue and earnings than Roivant Sciences. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,499.16	-$299.77M	-$0.60	N/A
Protagonist Therapeutics	$46.02M	133.33	-$130.15M	-$1.81	N/A

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential upside of 17.04%. Protagonist Therapeutics has a consensus target price of $115.21, suggesting a potential upside of 20.76%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Protagonist Therapeutics had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.42 beat Protagonist Therapeutics' score of 0.72 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics beats Roivant Sciences on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Moderna?

Protagonist Therapeutics (NASDAQ:PTGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Protagonist Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Protagonist Therapeutics presently has a consensus target price of $115.21, indicating a potential upside of 20.76%. Moderna has a consensus target price of $35.73, indicating a potential downside of 27.16%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protagonist Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Moderna had 19 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 27 mentions for Moderna and 8 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.72 beat Moderna's score of 0.46 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

Protagonist Therapeutics has higher earnings, but lower revenue than Moderna. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	133.33	-$130.15M	-$1.81	N/A
Moderna	$1.94B	10.01	-$2.82B	-$8.15	N/A

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Moderna has a net margin of -143.55% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Protagonist Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Viatris?

Protagonist Therapeutics (NASDAQ:PTGX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Viatris has a net margin of -2.04% compared to Protagonist Therapeutics' net margin of -154.88%. Viatris' return on equity of 19.04% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Viatris	-2.04%	19.04%	7.62%

Protagonist Therapeutics presently has a consensus target price of $115.21, indicating a potential upside of 20.76%. Viatris has a consensus target price of $16.43, indicating a potential upside of 5.58%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Protagonist Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Viatris. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 1 mentions for Viatris. Viatris' average media sentiment score of 1.89 beat Protagonist Therapeutics' score of 0.72 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Protagonist Therapeutics	Positive
Viatris	Very Positive

Protagonist Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	133.33	-$130.15M	-$1.81	N/A
Viatris	$14.30B	1.27	-$3.51B	-$0.26	N/A

Summary

Protagonist Therapeutics beats Viatris on 11 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.14B	$3.28B	$6.25B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-52.71	17.91	22.28	24.19
Price / Sales	133.33	324.60	581.86	138.32
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	9.71	6.64	9.84	6.72
Net Income	-$130.15M	$24.20M	$3.57B	$337.19M
7 Day Performance	-6.65%	-3.17%	-1.15%	0.53%
1 Month Performance	-3.01%	0.57%	3.85%	5.10%
1 Year Performance	86.86%	47.29%	27.43%	34.36%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	2.486 of 5 stars	$95.41 +2.3%	$115.21 +20.8%	+85.8%	$6.14B	$46.02M	N/A	120	Insider Trade
BNTX BioNTech	3.6722 of 5 stars	$95.95 +2.7%	$129.56 +35.0%	-21.2%	$23.63B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7565 of 5 stars	$106.91 -1.3%	$210.95 +97.3%	+44.7%	$23.49B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	2.9204 of 5 stars	$29.99 +0.4%	$33.59 +12.0%	+152.9%	$21.39B	$8.26M	N/A	860
MRNA Moderna	1.5032 of 5 stars	$47.19 -0.8%	$35.73 -24.3%	+68.7%	$18.88B	$1.94B	N/A	4,700	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BNTX, INSM, ROIV, MRNA, and VTRS

How does Protagonist Therapeutics compare to BioNTech?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Summary

How does Protagonist Therapeutics compare to Moderna?

Summary

How does Protagonist Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. BNTX, INSM, ROIV, MRNA, and VTRS

How does Protagonist Therapeutics compare to BioNTech?

Is BNTX or PTGX more profitable?

Do analysts rate BNTX or PTGX?

Do institutionals and insiders have more ownership in BNTX or PTGX?

Which has stronger earnings & valuation, BNTX or PTGX?

Does the media prefer BNTX or PTGX?

Which has more risk & volatility, BNTX or PTGX?

Summary

How does Protagonist Therapeutics compare to Insmed?

Does the media prefer INSM or PTGX?

Do insiders & institutionals have more ownership in INSM or PTGX?

Which has more volatility & risk, INSM or PTGX?

Is INSM or PTGX more profitable?

Do analysts prefer INSM or PTGX?

Which has better earnings & valuation, INSM or PTGX?

Summary

How does Protagonist Therapeutics compare to Roivant Sciences?

Is ROIV or PTGX more profitable?

Do insiders and institutionals hold more shares of ROIV or PTGX?

Which has higher valuation & earnings, ROIV or PTGX?

Which has more volatility & risk, ROIV or PTGX?

Do analysts recommend ROIV or PTGX?

Does the media prefer ROIV or PTGX?

Summary

How does Protagonist Therapeutics compare to Moderna?

Which has more volatility & risk, PTGX or MRNA?

Do analysts rate PTGX or MRNA?

Does the media favor PTGX or MRNA?

Which has better earnings and valuation, PTGX or MRNA?

Do institutionals and insiders believe in PTGX or MRNA?

Is PTGX or MRNA more profitable?

Summary

How does Protagonist Therapeutics compare to Viatris?

Do institutionals & insiders have more ownership in PTGX or VTRS?

Is PTGX or VTRS more profitable?

Do analysts prefer PTGX or VTRS?

Does the media favor PTGX or VTRS?

Which has more risk & volatility, PTGX or VTRS?

Which has stronger earnings and valuation, PTGX or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools